The epidemiology of sickle cell disease in children recruited in infancy in Kilifi, Kenya: a prospective cohort study.


Journal

The Lancet. Global health
ISSN: 2214-109X
Titre abrégé: Lancet Glob Health
Pays: England
ID NLM: 101613665

Informations de publication

Date de publication:
10 2019
Historique:
received: 16 02 2019
revised: 02 07 2019
accepted: 05 07 2019
pubmed: 28 8 2019
medline: 27 5 2020
entrez: 28 8 2019
Statut: ppublish

Résumé

Sickle cell disease is the most common severe monogenic disorder in humans. In Africa, 50-90% of children born with sickle cell disease die before they reach their fifth birthday. In this study, we aimed to describe the comparative incidence of specific clinical outcomes among children aged between birth and 5 years with and without sickle cell disease, who were resident within the Kilifi area of Kenya. This prospective cohort study was done on members of the Kilifi Genetic Birth Cohort Study (KGBCS) on the Indian Ocean coast of Kenya. Recruitment to the study was facilitated through the Kilifi Health and Demographic Surveillance System (KHDSS), which covers a resident population of 260 000 people, and was undertaken between Jan 1, 2006, and April 30, 2011. All children who were born within the KHDSS area and who were aged 3-12 months during the recruitment period were eligible for inclusion. Participants were tested for sickle cell disease and followed up for survival status and disease-specific admission to Kilifi County Hospital by passive surveillance until their fifth birthday. Children with sickle cell disease were offered confirmatory testing and care at a dedicated outpatient clinic. 15 737 infants were recruited successfully to the KGBCS, and 128 (0·8%) of these infants had sickle cell disease, of whom 70 (54·7%) enrolled at the outpatient clinic within 12 months of recruitment. Mortality was higher in children with sickle cell disease (58 per 1000 person-years of observation, 95% CI 40-86) than in those without sickle cell disease (2·4 per 1000 person-years of observation, 2·0-2·8; adjusted incidence rate ratio [IRR] 23·1, 95% CI 15·1-35·3). Among children with sickle cell disease, mortality was lower in those who enrolled at the clinic (adjusted IRR 0·26, 95% CI 0·11-0·62) and in those with higher levels of haemoglobin F (HbF; adjusted IRR 0·40, 0·17-0·94). The incidence of admission to hospital was also higher in children with sickle cell disease than in children without sickle cell disease (210 per 1000 person-years of observation, 95% CI 174-253, vs 43 per 1000 person-years of observation, 42-45; adjusted IRR 4·80, 95% CI 3·84-6·15). The most common reason for admission to hospital among those with sickle cell disease was severe anaemia (incidence 48 per 1000 person-years of observation, 95% CI 32-71). Admission to hospital was lower in those with a recruitment HbF level above the median (IRR 0·43, 95% CI 0·24-0·78; p=0·005) and those who were homozygous for α-thalassaemia (0·07, 0·01-0·83; p=0·035). Although morbidity and mortality were high in young children with sickle cell disease in this Kenyan cohort, both were reduced by early diagnosis and supportive care. The emphasis must now move towards early detection and prevention of long-term complications of sickle cell disease. Wellcome Trust.

Sections du résumé

BACKGROUND
Sickle cell disease is the most common severe monogenic disorder in humans. In Africa, 50-90% of children born with sickle cell disease die before they reach their fifth birthday. In this study, we aimed to describe the comparative incidence of specific clinical outcomes among children aged between birth and 5 years with and without sickle cell disease, who were resident within the Kilifi area of Kenya.
METHODS
This prospective cohort study was done on members of the Kilifi Genetic Birth Cohort Study (KGBCS) on the Indian Ocean coast of Kenya. Recruitment to the study was facilitated through the Kilifi Health and Demographic Surveillance System (KHDSS), which covers a resident population of 260 000 people, and was undertaken between Jan 1, 2006, and April 30, 2011. All children who were born within the KHDSS area and who were aged 3-12 months during the recruitment period were eligible for inclusion. Participants were tested for sickle cell disease and followed up for survival status and disease-specific admission to Kilifi County Hospital by passive surveillance until their fifth birthday. Children with sickle cell disease were offered confirmatory testing and care at a dedicated outpatient clinic.
FINDINGS
15 737 infants were recruited successfully to the KGBCS, and 128 (0·8%) of these infants had sickle cell disease, of whom 70 (54·7%) enrolled at the outpatient clinic within 12 months of recruitment. Mortality was higher in children with sickle cell disease (58 per 1000 person-years of observation, 95% CI 40-86) than in those without sickle cell disease (2·4 per 1000 person-years of observation, 2·0-2·8; adjusted incidence rate ratio [IRR] 23·1, 95% CI 15·1-35·3). Among children with sickle cell disease, mortality was lower in those who enrolled at the clinic (adjusted IRR 0·26, 95% CI 0·11-0·62) and in those with higher levels of haemoglobin F (HbF; adjusted IRR 0·40, 0·17-0·94). The incidence of admission to hospital was also higher in children with sickle cell disease than in children without sickle cell disease (210 per 1000 person-years of observation, 95% CI 174-253, vs 43 per 1000 person-years of observation, 42-45; adjusted IRR 4·80, 95% CI 3·84-6·15). The most common reason for admission to hospital among those with sickle cell disease was severe anaemia (incidence 48 per 1000 person-years of observation, 95% CI 32-71). Admission to hospital was lower in those with a recruitment HbF level above the median (IRR 0·43, 95% CI 0·24-0·78; p=0·005) and those who were homozygous for α-thalassaemia (0·07, 0·01-0·83; p=0·035).
INTERPRETATION
Although morbidity and mortality were high in young children with sickle cell disease in this Kenyan cohort, both were reduced by early diagnosis and supportive care. The emphasis must now move towards early detection and prevention of long-term complications of sickle cell disease.
FUNDING
Wellcome Trust.

Identifiants

pubmed: 31451441
pii: S2214-109X(19)30328-6
doi: 10.1016/S2214-109X(19)30328-6
pmc: PMC7024980
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1458-e1466

Subventions

Organisme : Wellcome Trust
ID : 202800/Z/16/Z
Pays : United Kingdom

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.

Références

Lancet. 2002 Apr 13;359(9314):1311-2
pubmed: 11965279
Am J Bioeth. 2013;13(4):20-2
pubmed: 23514390
Int J Epidemiol. 2012 Jun;41(3):650-7
pubmed: 22544844
BMC Med. 2014 Oct 22;12:200
pubmed: 25604462
Arch Pediatr. 1998 Sep;5(9):965-9
pubmed: 9789626
Blood. 2017 Nov 16;130(20):2215-2223
pubmed: 28931524
Nat Genet. 2014 Nov;46(11):1197-204
pubmed: 25261933
Lancet. 2009 Oct 17;374(9698):1364-70
pubmed: 19747721
Am J Hematol. 2013 Dec;88(12):984-9
pubmed: 24038490
Lancet. 2011 Oct 8;378(9799):1316-23
pubmed: 21903251
Br J Haematol. 2009 Sep;146(6):675-82
pubmed: 19650883
Haematologica. 2019 May;104(5):e184-e186
pubmed: 30467202
PLoS One. 2013 Apr 09;8(4):e61130
pubmed: 23593408
PLoS One. 2011 Feb 16;6(2):e14699
pubmed: 21358818
Pediatrics. 1988 Jun;81(6):749-55
pubmed: 3368274
Trends Parasitol. 2011 Jul;27(7):315-20
pubmed: 21429801
Clin Infect Dis. 2009 Jul 15;49(2):216-22
pubmed: 19514855
Lancet. 1976 Jun 12;1(7972):1269-72
pubmed: 73695
N Engl J Med. 1994 Jun 9;330(23):1639-44
pubmed: 7993409
Am J Prev Med. 2011 Dec;41(6 Suppl 4):S398-405
pubmed: 22099364
BMC Med Ethics. 2013 Oct 14;14:41
pubmed: 24125465
Bull World Health Organ. 2008 Jun;86(6):480-7
pubmed: 18568278
J Clin Pathol. 2009 Jan;62(1):46-8
pubmed: 19103860
Lancet. 2008 Nov 1;372(9649):1555-62
pubmed: 18984188
Am J Hematol. 2018 Mar;93(3):363-370
pubmed: 29168218
Curr Opin Hematol. 2006 May;13(3):131-6
pubmed: 16567954
Nat Genet. 2005 Nov;37(11):1253-7
pubmed: 16227994
Ethn Health. 2011 Aug-Oct;16(4-5):343-59
pubmed: 21797722
N Engl J Med. 2019 Jan 10;380(2):121-131
pubmed: 30501550
N Engl J Med. 2005 Jan 6;352(1):39-47
pubmed: 15635111
Lancet. 2013 Jan 12;381(9861):142-51
pubmed: 23103089
J Clin Pathol. 2009 Jan;62(1):35-8
pubmed: 19103857
Nat Commun. 2019 Feb 20;10(1):856
pubmed: 30787300
Hematol Oncol Clin North Am. 2016 Apr;30(2):343-58
pubmed: 27040958
BMJ. 2005 Feb 26;330(7489):432-3
pubmed: 15731125

Auteurs

Sophie Uyoga (S)

KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.

Alex W Macharia (AW)

KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.

George Mochamah (G)

KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.

Carolyne M Ndila (CM)

KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.

Gideon Nyutu (G)

KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.

Johnstone Makale (J)

KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.

Metrine Tendwa (M)

KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.

Emily Nyatichi (E)

KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.

John Ojal (J)

KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.

Mark Otiende (M)

KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.

Mohammed Shebe (M)

KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.

Kennedy O Awuondo (KO)

KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.

Neema Mturi (N)

KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.

Norbert Peshu (N)

KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.

Benjamin Tsofa (B)

KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.

Kathryn Maitland (K)

KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya; Faculty of Medicine, Imperial College, St Mary's Hospital, London, UK.

J Anthony G Scott (JAG)

KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya; London School of Hygiene & Tropical Medicine, London, UK; INDEPTH Network, Accra, Ghana.

Thomas N Williams (TN)

KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya; London School of Hygiene & Tropical Medicine, London, UK; INDEPTH Network, Accra, Ghana. Electronic address: twilliams@kemri-wellcome.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH